Pacific Cancer Care will use Deep Lens’ artificial intelligence (AI)-based solutions to streamline its clinical trial matching and expedite enrolment for cancer patients after the companies entered a partnership.

The collaboration will extend Pacific Cancer Care’s current clinical trial offering to people by precisely and efficiently detecting eligible patients for trials, boosting communications between patient care groups and taking more trials to the practice.

According to estimates, more than 15,000 cancer trials are actively enrolling subjects, but less than one in 30 patients take part in a trial.

Reduced trial site resources make it time-consuming to detect eligible subjects, especially when the complexity of the trial protocols rises.

Deep Lens’ AI solution VIPER automates the process of detecting potentially eligible subjects during diagnosis and matches them to related trials and offers support to care teams.

By pre-screening all patients from EMR (OncoEMR) of Pacific Cancer Care, VIPER can merge molecular data feeds from Caris Life Sciences, Foundation Medicine and Guardant Health, and all pathology feeds to automatically find qualified subjects for trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The pre-screening and trial matching solution of Deep Lens is offered at zero cost to oncology practices.

Pacific Cancer Care oncologist Zach Koontz said: “Clinical trials are not only critical to the advancement of new therapeutic options for cancer, but they present a unique opportunity for patients to access novel treatments well in advance of their commercialization, some of which may help positively impact the state of their disease.

“We are excited to partner with Deep Lens to broaden our clinical research program through an increased number of trials that we can offer onsite and by expediting the time we can get patients into these trials.”

In June this year, the Center for Cancer and Blood Disorders (The CenterTX) in the US announced plans to deploy Deep Lens’ AI-based clinical trial screening and enrolment solution VIPER.